Andrographolide Reverses Doxorubicin Resistance in Human Breast Cancer Stem Cells by Regulating Apoptotic Gene Expressions
Abstract
BACKGROUND: Breast cancer stem cells (BCSCs) have been identified as playing a crucial role in therapeutic resistance. This resistance can be attributed to the anti-apoptotic protein survivin and the antioxidant MnSOD high expression. To overcome the resistance to doxorubicin (DOX), this study proposed the utilization of andrographolide (ANDRO), the primary bioactive compound in Andrographis paniculata leaves. The objective was to examine the role of andrographolide in regulating survivin, caspase-9, and caspase-3 gene expressions to reverse doxorubicin resistance in human BCSCs.
METHODS: BCSCs were exposed to 0.1 µM DOX every two days or 50 µM rotenone (ROT) for 6 hours, subsequently supplemented with 0.3 mM ANDRO. Superoxide and peroxide levels were measured using DHE and DCFH-DA assay. The MnSOD, survivin, caspase-9, and caspase-3 mRNA expression levels were analyzed using qRT-PCR. Protein expressions were evaluated using Western blotting assay. MnSOD activity was determined using xanthine oxidase inhibition assay. The apoptotic cells were determined using Annexin-V/PI staining.
RESULTS: This study indicated that the cytotoxic mechanisms of DOX, similar to ROT, in BCSCs were attributed to oxidative stress, as evidenced by an elevation in superoxide rather than peroxide levels, accompanied by a decrease in MnSOD activity. This study also highlighted that ANDRO reversed DOX resistance in BCSCs subjected to repeated DOX treatment by downregulating survivin and upregulating caspase-9 and caspase-3 mRNA expressions, thereby activating the intrinsic apoptotic pathway.
CONCLUSION: This study provides insights into the role of ANDRO in modulating the expression of apoptotic genes, such as survivin, caspase-9, and caspase-3, to overcome DOX resistance in BCSCs.
KEYWORDS: breast cancer, breast cancer stem cell, andrographolide, doxorubicin, oxidative stress, apoptosis
Full Text:
PDFReferences
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-49, CrossRef.
Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: A 25-year study. Asian Pac J Cancer Prev. 2019; 20(7): 2015-20, CrossRef.
Parsons J, Francavilla C. 'Omics approaches to explore the breast cancer landscape. Front Cell Dev Biol. 2019; 7: 395, CrossRef.
Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clin. 2018; 13(3): 339-54, CrossRef.
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020; 5(1): 8. doi: 10.1038/s41392-020-0110-5, CrossRef.
Shibata M, Hoque MO. Targeting cancer stem cells: A strategy for effective eradication of cancer. Cancers. 2019; 11(5): 732, CrossRef.
Nadia YF, Syahrani RA, Arumsari S, Sadikin M, Wanandi SI. Effect of cell culture medium on the proliferation and stemness of CD24-/CD44+ human breast cancer stem cells. Indones Biomed J. 2021; 13(4): 355-63, CrossRef.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100(7): 3983-8, CrossRef.
Lindeman GJ, Visvader JE. Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia Pac J Clin Oncol. 2010; 6(2): 89-97, CrossRef.
Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, et al. Doxorubicin in combination with a small TGFbeta inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PLoS One. 2010; 5(4): e10365, CrossRef.
Micallef I, Baron B. Doxorubicin: An overview of the anti-cancer and chemoresistance mechanisms. Annals of Clinical Toxicology. 2020; 3(2): 1031, article.
Syahrani RA, Louisa M, Wanandi SI. Sensitivity of breast cancer stem cells (Cd24-/Cd44+) to Doxorubicin is associated with oxidative stress status. Int J Appl Pharm. 2019; 11(6): 91-6, CrossRef.
Wanandi SI, Syahrani RA, Jusman SWA. 8P - The impact of rotenone-modulated oxidative stress on the survival of human breast cancer stem cells (CD24-/CD44+). Ann Oncol. 2017; 28 (Suppl 5): v3, CrossRef.
Chen X, Duan N, Zhang C, Zhang W. Survivin and tumorigenesis: Molecular mechanisms and therapeutic strategies. J Cancer. 2016; 7(3): 314-23, CrossRef.
Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014; 15(2): 2494-516, CrossRef.
Rahman MN, Wijaya CR, Novalentina M. Survivin clinical features in cervical cancer. Mol Cell Biomed Sci. 2017; 1(1): 6-16, CrossRef.
Sandra F. Survivin Ser81 plays an important role in PI3K/Akt/mTOR signaling pathway. Mol Cell Biomed Sci. 2018; 2(2): 55-9, CrossRef.
Jarukamjorn K, Nemoto N. Pharmacological aspects of Andrographis paniculata on health and its major diterpenoid constituent andrographolide. J Health Sci. 2008; 54(4): 370-81, CrossRef.
Chao WW, Kuo YH, Lin BF. Isolation and identification of Andrographis paniculata (Chuanxinlian) and its biologically active constituents inhibited enterovirus 71-induced cell apoptosis. Front Pharmacol. 2021; 12: 762285, CrossRef.
Adiguna SP, Panggabean JA, Swasono RT, Rahmawati SI, Izzati F, Bayu A, et al. Evaluations of andrographolide-rich fractions of Andrographis paniculata with enhanced potential antioxidant, anticancer, antihypertensive, and anti-inflammatory activities. Plants. 2023; 12(6): 1220, CrossRef.
Wanandi SI, Limanto A, Yunita E, Syahrani RA, Louisa M, Wibowo AE, et al. In silico and in vitro studies on the anti-cancer activity of andrographolide targeting survivin in human breast cancer stem cells. PLoS One. 2020; 15(11): e0240020, CrossRef.
Shiraishi A, Tachi K, Essid N, Tsuboi I, Nagano M, Kato T, et al. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells. Cancer Sci. 2017; 108(3): 362-72, CrossRef.
Wanandi SI, Syahrani RA, Arumsari S, Wideani G, Hardiany NS. Profiling of gene expression associated with stemness and aggressiveness of ALDH1A1-expressing human breast cancer cells. Malays J Med Sci. 2019; 26(5): 38-52, CrossRef.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001; 25(4): 402-8, CrossRef.
Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. Sci Rep. 2017; 7: 45465, CrossRef.
Ochi R, Dhagia V, Lakhkar A, Patel D, Wolin MS, Gupte SA. Rotenone-stimulated superoxide release from mitochondrial complex I acutely augments L-type Ca2+ current in A7r5 aortic smooth muscle cells. Am J Physiol Heart Circ Physiol. 2016; 310(9): H1118-28, CrossRef.
Rachman AT, Suraduhita A, Syahrani RA, Louisa M, Wanandi SI. Suppression of MnSOD by andrographolide and its relation to oxidative stress and viability of breast cancer stem cells treated with repeated doxorubicin administration. 1st Jenderal Soedirman International Medical Conference (JIMC) 2020. Proceedings of the 1st Jenderal Soedirman International Medical Conference in conjunction with the 5th Annual Scientific Meeting (Temilnas) Consortium of Biomedical Science Indonesia 2020, November 28 – 29, 2020. Setúbal, Portugal: SCITEPRESS; 2021. p. 28-34, article.
Holley AK, Bakthavatchalu V, Velez-Roman JM, St Clair DK. Manganese superoxide dismutase: Guardian of the powerhouse. Int J Mol Sci. 2011; 12(10): 7114-62, CrossRef.
Li M, Chiu JF, Mossman BT, Fukagawa NK. Down-regulation of manganese-superoxide dismutase through phosphorylation of FOXO3a by Akt in explanted vascular smooth muscle cells from old rats. J Biol Chem. 2006; 281(52): 40429-39, CrossRef.
Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D, et al. Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta. 2012; 1822(5): 794-814, CrossRef.
Cho SJ, Park JW, Kang JS, Kim WH, Juhnn YS, Lee JS, et al. Nuclear factor-kappaB dependency of doxorubicin sensitivity in gastric cancer cells is determined by manganese superoxide dismutase expression. Cancer Sci. 2008; 99(6): 1117-24, CrossRef.
Fu A, Ma S, Na W, Tan BXX, Tan EY, Luo KQ. High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin. Oncotarget. 2016; 7(31): 50239-57, CrossRef.
Miller CJ, Gounder SS, Kannan S, Goutam K, Muthusamy VR, Firpo MA, et al. Disruption of Nrf2/ARE signaling impairs antioxidant mechanisms and promotes cell degradation pathways in aged skeletal muscle. Biochim Biophys Acta. 2012; 1822(6): 1038-50, CrossRef.
Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, et al. Nrf2 Signaling pathway in chemoprotection and doxorubicin resistance: Potential application in drug discovery. Antioxidants. 2021; 10(3): 349, CrossRef.
Yu C, Ou J, Wang M, Jialielihan N, Liu Y. Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells. JBUON. 2015; 20(5): 1287-94, PMID.
Yousefnia S, Seyed Forootan F, Seyed Forootan S, Nasr Esfahani MH, Gure AO, Ghaedi K. Mechanistic pathways of malignancy in breast cancer stem cells. Front Oncol. 2020; 10: 452, CrossRef.
Hart PC, Mao M, de Abreu AL, Ansenberger-Fricano K, Ekoue DN, Ganini D, et al. MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK- dependent signalling in cancer. Nat Commun. 2015; 6: 6053, CrossRef.
Wani TH, Chowdhury G, Chakrabarty A. Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155). RSC Med Chem. 2021; 12(4): 566-78, CrossRef.
DOI: https://doi.org/10.18585/inabj.v15i5.2596
Copyright (c) 2023 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
